What is Marksans Pharma Ltd (MARKSANS) share price return in the past 10 years?

Marksans Pharma Ltd share price has appreciated 18.2% annually (CAGR) over the past ten years.

What is the share price of Marksans Pharma Ltd (MARKSANS)?

Company share prices are keep on changing according to the market conditions. The current trading price of Marksans Pharma Ltd (MARKSANS) on 08-Jun-2026 16:59:59 at 16:59 is 236.05.

What is the P/E ratio of Marksans Pharma?

The latest standalone P/E ratio of Marksans Pharma as of 08-Jun-2026 is 35.57.

What is the P/B ratio of Marksans Pharma Ltd (MARKSANS)?

The latest standalone P/B ratio of Marksans Pharma Ltd (MARKSANS) as of 08-Jun-2026 is 6.47.

What is the 52-week high and low of Marksans Pharma Ltd (MARKSANS)?

The 52-week high of Marksans Pharma Ltd (MARKSANS) is Rs. 270.60 and the 52-week low is Rs. 156.00.

Marksans Pharma Ltd (MARKSANS) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Marksans Pharma Ltd (MARKSANS)
Brand: Marksans Pharma

Key Metrics

Valuation Multiples

Market Cap

₹10,697 Cr.

Current Price

₹236.1

52-Week Low / High

₹156 / 271

TTM EPS

₹6.6

TTM Sales

₹1,341 Cr.

Book Value per Share

₹36.5

P/E Ratio

35.57

In line with its 5-year historical median

Industry PE

46.6

Price to Book (P/B)

6.47

Higher than its 5-year historical median

Price to Sales (P/S)

7.97

Higher than its 5-year historical median

EV/EBITDA

24.00

In line with its 5-year historical median

Dividend Yield

0.36%

Profitability Efficiency

Return on Equity (ROE)

14.45%

Outperforms industry median

Return on Capital Employed (ROCE)

18.76%

Outperforms industry median

Return on Assets (ROA)

11.26%

Operating Profit Margin

17.7%

Net Profit Margin

16.03%

Gross Profit Margin

23.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

37.63%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

45.81%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

40.75%

Asset Quality

Promoter Holding

43.87%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹1,607 Cr.

Equity

₹45.3 Cr.

Face Value

₹1

All Time Low / High

₹0.70 / 358.50

Marksans Pharma stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Marksans Pharma Ltd a good quality company?

Marksans Pharma Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Marksans Pharma Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Marksans Pharma Ltd vs industry peers?

Marksans Pharma Ltd revenue CAGR is 22.06%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Marksans Pharma Ltd?

Promoters hold 43.87% of the Marksans Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Marksans Pharma Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 16.9% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	22.5%	3.4%	4.9%	12%	11.4%	23.5%	19.9%	14.3%	14.8%	18.8%	-
Value Creation Index ⓘ	0.6	-0.8	-0.7	-0.1	-0.2	0.7	0.4	0.0	0.1	0.4	-
Growth Parameters ⓘ
Sales ⓘ	358	216	295	424	433	600	658	655	853	1,174	1,341
Sales YoY Gr.	-	-39.7%	36.5%	44%	2.2%	38.3%	9.8%	-0.5%	30.2%	37.6%	-
Adj EPS ⓘ	1.7	0.1	0.2	1	0.9	2.4	2.2	1.8	2.8	3.9	6.6
YoY Gr.	-	-94%	80%	450%	-6.1%	160.2%	-9.5%	-16.4%	54.1%	36.5%	-
BVPS (₹) ⓘ	10	10.2	10.5	11.5	12.4	14.7	16.9	24.5	27	30.5	36.5
Adj Net Profit ⓘ	68.3	3.9	7.3	40.7	37.9	99.1	89.5	83.1	128	175	301
Cash Flow from Ops. ⓘ	64.8	-13.6	15.6	19.8	108	107	56	51.7	34.1	31	-
Debt/CF from Ops. ⓘ	0.6	-5.4	4.3	3.9	0	0	0.1	0	0	0	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	14.1%	22.1%	21.3%	37.6%
Adj EPS ⓘ	9.7%	32.9%	20.7%	36.5%
BVPSⓘ	13.2%	19.8%	21.8%	13.2%
Share Price	18.2%	27.6%	38.4%	-6.7%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	17.5	0.9	1.7	9	7.8	17.9	12.9	8.8	11	13.4	19.8
Op. Profit Mgn % ⓘ	27.8	6.3	9.9	14.9	16.5	19.1	17.3	12.8	16.4	17.7	24.1
Net Profit Mgn % ⓘ	19.1	1.8	2.5	9.6	8.8	16.5	13.6	12.7	15	14.9	22.4
Debt to Equity ⓘ	0.1	0.2	0.2	0.2	0	0	0	0	0	0	0
Working Cap Days ⓘ	206	352	278	223	227	165	187	238	253	240	161
Cash Conv. Cycle ⓘ	127	260	208	160	157	105	121	146	143	133	121

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	358	216	295	424	433	600	658	655	853	1,174
Operating Expenses ⓘ +	259	202	266	361	362	486	545	582	713	970
Manufacturing Costs	22	19	19	21	18	23	17	40	72	95
Material Costs	178	112	169	236	245	338	378	394	479	640
Employee Cost	26	40	46	46	49	55	60	56	77	102
Other Costs ⓘ	33	31	32	57	50	70	90	91	85	133
Operating Profit ⓘ	99	14	29	63	71	114	114	73	140	204
Operating Profit Margin (%)	27.7%	6.3%	9.9%	14.9%	16.5%	19.0%	17.3%	11.1%	16.4%	17.4%
Other Income ⓘ +	13	18	7	8	0	31	42	79	62	70
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	6	4	8	7	7	5	4	4	1	1
Depreciation ⓘ	15	15	12	9	12	15	18	17	29	29
Profit Before Tax ⓘ	92	12	17	56	53	124	135	132	172	243
Tax ⓘ	20	0	4	12	15	26	31	29	38	55
Profit After Tax	71	12	12	44	38	98	104	103	134	188
PAT Margin (%)	20.0%	5.4%	4.2%	10.3%	8.8%	16.4%	15.8%	15.7%	15.7%	16.0%
Adjusted EPS (₹)	1.8	0.3	0.3	1.1	0.9	2.4	2.5	2.3	3.0	4.2
Dividend Payout Ratio (%)	6.90%	17.70%	16.50%	4.70%	10.80%	10.40%	9.80%	22%	20.30%	19.30%

Valuation of Marksans Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	423	419	429	471	506	600	692	1,111	1,223	1,383
Share Capital ⓘ	53	41	41	41	41	41	41	45	45	45
Reserves ⓘ	369	378	388	430	465	559	651	1,066	1,177	1,338
Debt +	41	73	66	77	0	0	5	0	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	41	73	66	77	0	0	5	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	31	21	34	37	57	64	74	112	160	204
Others Liabilities ⓘ	39	33	31	40	48	97	218	146	166	209
Total Liabilities ⓘ	534	546	560	625	610	761	989	1,369	1,548	1,796
Fixed Assets
Net Fixed Assets ⓘ +	97	94	88	103	115	129	136	144	272	383
Gross Block	184	196	202	225	249	277	301	319	414	555
Accumulated Depreciation	87	102	114	122	134	148	166	175	143	172
CWIP ⓘ	0	0	0	0	0	0	0	4	0	0
Investments ⓘ	231	234	236	236	236	236	237	266	293	266
Inventories	44	29	42	70	75	94	104	131	191	205
Trade Receivables	133	155	169	178	162	169	247	305	370	550
Cash Equivalents	3	3	1	2	3	106	224	440	312	269
Others Assets ⓘ	25	31	24	36	19	27	43	78	111	123
Total Assets ⓘ	534	546	560	625	610	761	989	1,369	1,548	1,796

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	65	-14	16	20	108	107	56	52	34	31
PBT ⓘ	92	12	17	56	53	124	135	132	172	243
Adjustment ⓘ	9	13	20	12	19	-9	-8	11	-16	-8
Changes in Working Capital ⓘ	-15	-22	-16	-35	46	12	-39	-60	-83	-158
Tax Paid ⓘ	-20	-16	-5	-13	-10	-20	-32	-32	-39	-47
Cash Flow From Investing Activity ⓘ +	-177	-8	-8	-20	-24	9	-128	-195	-114	17
Capex	-22	-12	-6	-23	-24	-21	-23	-35	-155	-120
Net Investments	-164	-3	-2	0	0	0	-120	-149	-4	89
Others ⓘ	9	7	0	3	0	29	15	-10	45	48
Cash Flow From Financing Activity ⓘ +	-52	21	-10	1	-82	-14	71	210	-26	-30
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-3	-4	-8	-7	-7	-5	-3	-4	0	0
Dividend Paid ⓘ	-7	-6	-2	-2	-2	-4	-11	-10	-23	-27
Others ⓘ	-42	31	0	10	-72	-4	85	224	-4	-3
Net Cash Flow ⓘ	-164	-1	-2	1	2	102	-1	67	-106	18

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	18.91	2.79	2.93	9.7	7.77	17.8	16.11	11.41	11.46	14.45
ROCE (%)	22.45	3.44	4.92	11.99	11.39	23.46	19.91	14.27	14.81	18.76
Asset Turnover Ratio	0.67	0.4	0.53	0.72	0.7	0.88	0.76	0.59	0.59	0.7
PAT to CFO Conversion(x)	0.92	-1.17	1.33	0.45	2.84	1.09	0.54	0.5	0.25	0.16
Working Capital Days
Receivable Days	131.50	243.70	200.50	149.20	143	99.90	114	144.90	144.10	142.40
Inventory Days	48.30	61.70	44.30	48.50	61	50.80	54.10	61.60	68.70	61.30
Payable Days	77.80	84.50	58.50	54.80	69.80	65.30	67	86.10	103.40	103.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Marksans Pharma Ltd FAQs

The current trading price of Marksans Pharma on 08-Jun-2026 16:59 is ₹236.1.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 07-Jun-2026 the market cap of Marksans Pharma stood at ₹10,696.9 Cr

The latest P/E ratio of Marksans Pharma as of 07-Jun-2026 is 35.57.

The latest P/B ratio of Marksans Pharma as of 07-Jun-2026 is 6.47.

The 52-week high of Marksans Pharma is ₹270.6 and the 52-week low is ₹156.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Marksans Pharma is ₹1,341 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Marksans Pharma Ltd is a average quality company.

The key valuation ratios of Marksans Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Marksans Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Marksans Pharma Ltd

Marksans Pharma is at the forefront of the pharmaceutical industry, distinguished by a customer-centric approach. Specializing in Over-the-Counter (OTC) and prescription drugs, the company has cultivated a strong presence in highly regulated markets. Leveraging robust Research and Development (R&D) capabilities and advanced manufacturing facilities both domestically and internationally, the company is among the top five Indian Companies in the United Kingdom. The company’s strategic emphasis on optimizing supply chain efficiencies has facilitated substantial business expansion across key global markets. The company’s high-quality and expansive portfolio has led to a growing foothold in the USA as well.

Headquartered in Mumbai, the company has built a robust global footprint, actively operating in over several countries worldwide. The company’s integrated business approach, supported by a talented workforce, positions it for sustained long-term growth with a focus on value creation. The company’s key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Pain Management, Cough and Cold, Digestives, CVS, CNS Oncology, Antidiabetic, and Antibiotics, among others.

At the core of its operations is an unwavering commitment to quality. Rigorous Quality Control (QC) and Quality Assurance (QA) processes have positioned it as a niche player in the pharmaceutical ecosystem. Adherence to Current Good Manufacturing Practices (cGMP) norms is integral to its operations. Continuous improvement initiatives across products, processes, and skills ensure its offerings evolve to meet changing client needs. The company’s world-class manufacturing facilities have garnered approval from esteemed institutions such as the US FDA, UK MHRA, Australian TGA, and other foreign health authorities.

Business area of the company

The company is a globally-trusted, customer-centric pharmaceutical company with a strong presence in regulated markets. The company specialises in developing and manufacturing & distributing both over-the-counter (OTC) and prescription (Rx) drugs, aligning its offerings with the evolving needs of patients and healthcare providers across the world.

Formulations business product portfolio

Tablets (plain, enteric-coated and film-coated)
Hard capsules
Soft gelatin capsules
Oral liquids
Ointments

Consumer Self-Care Products

Pain Management - Arthritis
Upper Respiratory - Cough & Cold and Allergy
Digestive Health
VMS (Vitamins Minerals and Supplements)
Skin Care Products

Prescription - Rx Therapeutic Segments

Cardiovascular System (CVS)
Central Nervous System (CNS)
Oncology
Anti-Diabetics
Anti-Biotic

Milestones

2001: Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.
2003: Spun off into a separate entity – Glenmark Laboratories Ltd.
2003: Changed its name to ‘Marksans Pharma Ltd’
2005: Acquired Nova Pharmaceuticals Australasia Pty Ltd
2007: Acquired Bell, Sons & Co. (Druggists) Ltd. UK
2008: Acquired Relonchem Ltd. UK
2009: Marksans Pharma establlished itself as a global player
2015: Acquired TimeCapLaboratories Inc. USA
2017: Increased focus on OTC segment in US market
2022: Acquired Access Healthcare Dubai
2023: Raised Rs 372.40 crore in equity via conversion of warrants issued to OrbiMed and Promoters.
2023: Acquired a manufacturing facility from Tevapharm India.
2024: Marksans crossed Rs 2,000 crore revenue.
2026: Incorporated two new wholly owned subsidiary companies by name Marksans Pharma (Europe) and Marksans (Canada) Inc.

Marksans Pharma Ltd (MARKSANS)

Marksans Pharma Ltd (MARKSANS)

Marksans Pharma stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Marksans Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Marksans Pharma Ltd FAQs

About Marksans Pharma Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Marksans Pharma Ltd (MARKSANS)

Marksans Pharma Ltd (MARKSANS)

Marksans Pharma stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Marksans Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Marksans Pharma Ltd FAQs

What is the share price of Marksans Pharma?

What is the market cap of Marksans Pharma?

What is the P/E ratio of Marksans Pharma?

What is the P/B ratio of Marksans Pharma?

What is the 52-week high and low of Marksans Pharma?

What is the TTM revenue of Marksans Pharma?

Is Marksans Pharma Ltd a good quality company?

Is Marksans Pharma Ltd undervalued or overvalued?

Is Marksans Pharma Ltd a good buy now?

About Marksans Pharma Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.